SLU-PP-332 side effects and results in studies
No adverse events are reported for SLU-PP-332 in these records, because it has never been tested in people; a 2026 review of the mouse and cell work describes its effects as occurring without evident toxicity. The results measured are metabolic and cardiac outcomes in mice: energy expenditure, fat mass, insulin sensitivity, ejection fraction and survival.
SLU-PP-332 has no published human side-effect data in this record. It has not been through a clinical trial, so the adverse events that trials report for approved drugs, such as rates, severity and dropouts, do not exist for it. A 2026 systematic review of the preclinical literature says clinical trials are needed to confirm efficacy and safety in humans.
The closest thing to a safety statement is that review's summary that SLU-PP-332 and SLU-PP-915 reduced adiposity, improved glycaemic control and increased basal energy expenditure in obesity models without evident toxicity. The abstract gives no toxicology measures behind that phrase. In the mouse heart failure study, the ERR agonists improved heart function without changing cardiac hypertrophy, which the authors report as a neutral finding rather than a harm.
The results are clearer. In diet-induced obese and ob/ob mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, decreased fat mass and improved insulin sensitivity (Billon et al., 2024). In mice with pressure-overload heart failure, it improved ejection fraction, reduced fibrosis and increased survival, and ERRγ was shown to be the main mediator (Xu et al., 2024). The review adds more type IIa muscle fibres, better endurance and improved mitochondrial function in ageing kidneys across the preclinical studies it covered.
Two 2026 metabolism studies used human liver S9 fractions and microsomes to show how the compound is broken down, identifying hydroxylated, glucuronidated and sulfated metabolites. That work was done for anti-doping detection. It shows how the molecule is metabolised in a test tube, not whether it is safe in a person.
Adverse events reported
| Event | As reported | Source |
|---|---|---|
| Toxicity, overall (review of preclinical work) | Reduced adiposity and improved glycaemic control in obesity models were described as occurring without evident toxicity; no measures or rates given in the abstract | PMID 42024694 |
| Adverse effects in obese and ob/ob mice | Not reported in the abstract | Billon C et al. |
| Cardiac hypertrophy in the heart failure model | Not affected by SLU-PP-332 or SLU-PP-915 (mouse, pressure overload) | Xu W et al. |
| Human adverse events | No human studies in these records | PMID 42024694 |
Outcomes measured
| Outcome | Result as reported | Source |
|---|---|---|
| Energy expenditure and fatty acid oxidation | Increased in diet-induced obese and ob/ob mice | Billon C et al. |
| Fat mass | Decreased fat mass accumulation; obesity reduced in metabolic syndrome models | Billon C et al. |
| Insulin sensitivity | Improved in mouse models of metabolic syndrome | Billon C et al. |
| Ejection fraction, fibrosis and survival in heart failure | Ejection fraction improved, fibrosis reduced and survival increased (mouse, pressure overload) | Xu W et al. |
| Cardiac metabolic profile | Substantial normalisation of fatty acid/lipid and TCA/oxidative phosphorylation metabolites in the mouse heart after 6 weeks of pressure overload | Xu W et al. |
| Muscle fibres and endurance (review) | Pan-ERR agonists increased type IIa muscle fibres and improved endurance in preclinical models | PMID 42024694 |
| Ageing kidney (review) | Mitochondrial function restored and inflammation reduced in ageing kidneys | PMID 42024694 |
| Metabolites in human liver fractions | Nine metabolites identified: six Phase I metabolites and three Phase II conjugates | Möller T et al. |
What the studies don't show
There is no human safety data for SLU-PP-332 in these records, so its side effects in people are simply unknown. The mouse abstracts report benefits but give no adverse-event data, and the review's 'without evident toxicity' is a summary, not a measured toxicology study. The results are from mice, and none of them has been repeated in humans.